Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.

Opperman KS, Vandyke K, Clark KC, Coulter EA, Hewett DR, Mrozik KM, Schwarz N, Evdokiou A, Croucher PI, Psaltis PJ, Noll JE, Zannettino AC.

Neoplasia. 2019 Aug;21(8):777-787. doi: 10.1016/j.neo.2019.05.006. Epub 2019 Jun 24.

2.

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI.

Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25.

PMID:
31023703
3.

Using genomics to better define high-risk MGUS/SMM patients.

Dutta AK, Hewett DR, Fink JL, Zannettino ACW.

Oncotarget. 2018 Nov 27;9(93):36549-36550. doi: 10.18632/oncotarget.26390. eCollection 2018 Nov 27. No abstract available.

4.

Loss of EfnB1 in the osteogenic lineage compromises their capacity to support hematopoietic stem/progenitor cell maintenance.

Arthur A, Nguyen TM, Paton S, Zannettino ACW, Gronthos S.

Exp Hematol. 2019 Jan;69:43-53. doi: 10.1016/j.exphem.2018.10.004. Epub 2018 Oct 13.

5.

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K.

BMC Cancer. 2018 Oct 1;18(1):939. doi: 10.1186/s12885-018-4845-0. Review.

6.

mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis.

Martin SK, Fitter S, El Khawanky N, Grose RH, Walkley CR, Purton LE, Ruegg MA, Hall MN, Gronthos S, Zannettino ACW.

Sci Rep. 2018 Sep 28;8(1):14501. doi: 10.1038/s41598-018-32858-5.

7.

miRNA-376c-3p Mediates TWIST-1 Inhibition of Bone Marrow-Derived Stromal Cell Osteogenesis and Can Reduce Aberrant Bone Formation of TWIST-1 Haploinsufficient Calvarial Cells.

Camp E, Pribadi C, Anderson PJ, Zannettino ACW, Gronthos S.

Stem Cells Dev. 2018 Dec 1;27(23):1621-1633. doi: 10.1089/scd.2018.0083. Epub 2018 Oct 23.

PMID:
30229694
8.

The osteoprogenitor-specific loss of ephrinB1 results in an osteoporotic phenotype affecting the balance between bone formation and resorption.

Arthur A, Nguyen TM, Paton S, Klisuric A, Zannettino ACW, Gronthos S.

Sci Rep. 2018 Aug 24;8(1):12756. doi: 10.1038/s41598-018-31190-2.

9.

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.

Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW.

Leukemia. 2019 Feb;33(2):457-468. doi: 10.1038/s41375-018-0206-x. Epub 2018 Jul 25.

10.

Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?

Fitter S, Zannettino ACW.

Obes Res Clin Pract. 2018 May - Jun;12(3):249-250. doi: 10.1016/j.orcp.2018.06.004. No abstract available.

PMID:
29914635
11.

Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients.

Camp E, Anderson PJ, Zannettino ACW, Glackin CA, Gronthos S.

J Cell Physiol. 2018 Sep;233(9):7320-7332. doi: 10.1002/jcp.26563. Epub 2018 Apr 16.

PMID:
29663378
12.

Pentosan polysulfate binds to STRO-1+ mesenchymal progenitor cells, is internalized, and modifies gene expression: a novel approach of pre-programing stem cells for therapeutic application requiring their chondrogenesis.

Wu J, Shimmon S, Paton S, Daly C, Goldschlager T, Gronthos S, Zannettino ACW, Ghosh P.

Stem Cell Res Ther. 2017 Dec 13;8(1):278. doi: 10.1186/s13287-017-0723-y.

13.

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Hewett DR, Vandyke K, Lawrence DM, Friend N, Noll JE, Geoghegan JM, Croucher PI, Zannettino ACW.

Neoplasia. 2017 Dec;19(12):972-981. doi: 10.1016/j.neo.2017.09.004. Epub 2017 Nov 5.

14.

Mesenchymal progenitor cells primed with pentosan polysulfate promote lumbar intervertebral disc regeneration in an ovine model of microdiscectomy.

Daly CD, Ghosh P, Zannettino ACW, Badal T, Shimmon R, Jenkin G, Oehme D, Jain K, Sher I, Vais A, Cohen C, Chandra RV, Goldschlager T.

Spine J. 2018 Mar;18(3):491-506. doi: 10.1016/j.spinee.2017.10.008. Epub 2017 Oct 18.

PMID:
29055739
15.

HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.

Vandyke K, Zeissig MN, Hewett DR, Martin SK, Mrozik KM, Cheong CM, Diamond P, To LB, Gronthos S, Peet DJ, Croucher PI, Zannettino ACW.

Cancer Res. 2017 Oct 15;77(20):5452-5463. doi: 10.1158/0008-5472.CAN-17-0115. Epub 2017 Aug 30.

16.

Osteocalcin-dependent regulation of glucose metabolism and fertility: Skeletal implications for the development of insulin resistance.

Tangseefa P, Martin SK, Fitter S, Baldock PA, Proud CG, Zannettino ACW.

J Cell Physiol. 2018 May;233(5):3769-3783. doi: 10.1002/jcp.26163. Epub 2017 Sep 18. Review.

PMID:
28834550
17.

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.

Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A.

Cancer Med. 2017 Sep;6(9):2164-2176. doi: 10.1002/cam4.1115. Epub 2017 Aug 10.

18.

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.

Wallington-Beddoe CT, Bennett MK, Vandyke K, Davies L, Zebol JR, Moretti PAB, Pitman MR, Hewett DR, Zannettino ACW, Pitson SM.

Oncotarget. 2017 Jul 4;8(27):43602-43616. doi: 10.18632/oncotarget.17115.

19.

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.

Dutta AK, Hewett DR, Fink JL, Grady JP, Zannettino ACW.

Br J Haematol. 2017 Jul;178(2):196-208. doi: 10.1111/bjh.14649. Epub 2017 May 3. Review.

PMID:
28466550
20.

The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.

Vuckovic S, Vandyke K, Rickards DA, McCauley Winter P, Brown SHJ, Mitchell TW, Liu J, Lu J, Askenase PW, Yuriev E, Capuano B, Ramsland PA, Hill GR, Zannettino ACW, Hutchinson AT.

Br J Haematol. 2017 May;177(3):423-440. doi: 10.1111/bjh.14561. Epub 2017 Feb 17.

PMID:
28211573
21.

mTORC1 Plays an Important Role in Skeletal Development by Controlling Preosteoblast Differentiation.

Fitter S, Matthews MP, Martin SK, Xie J, Ooi SS, Walkley CR, Codrington JD, Ruegg MA, Hall MN, Proud CG, Gronthos S, Zannettino ACW.

Mol Cell Biol. 2017 Mar 17;37(7). pii: e00668-16. doi: 10.1128/MCB.00668-16. Print 2017 Apr 1.

22.

The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70.

Fitter S, Gronthos S, Ooi SS, Zannettino AC.

Stem Cells. 2017 Apr;35(4):940-951. doi: 10.1002/stem.2560. Epub 2017 Jan 23.

23.

EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation.

Nguyen TM, Arthur A, Zannettino AC, Gronthos S.

Exp Hematol. 2017 Apr;48:72-78. doi: 10.1016/j.exphem.2016.12.001. Epub 2016 Dec 14.

PMID:
27988259
24.

Histone deacetylases (HDAC) in physiological and pathological bone remodelling.

Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR.

Bone. 2017 Feb;95:162-174. doi: 10.1016/j.bone.2016.11.028. Epub 2016 Nov 30. Review.

PMID:
27913271
25.

Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.

Panagopoulos V, Liapis V, Zinonos I, Hay S, Leach DA, Ingman W, DeNichilo MO, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A.

Mol Cell Endocrinol. 2017 Jan 15;440:8-15. doi: 10.1016/j.mce.2016.11.007. Epub 2016 Nov 9.

PMID:
27836774
26.

Tyrosine kinase receptor c-ros-oncogene 1 mediates TWIST-1 regulation of human mesenchymal stem cell lineage commitment.

Camp E, Anderson PJ, Zannettino ACW, Gronthos S.

Bone. 2017 Jan;94:98-107. doi: 10.1016/j.bone.2016.09.019. Epub 2016 Sep 23.

PMID:
27669657
27.

Loss of ephrinB1 in osteogenic progenitor cells impedes endochondral ossification and compromises bone strength integrity during skeletal development.

Nguyen TM, Arthur A, Paton S, Hemming S, Panagopoulos R, Codrington J, Walkley CR, Zannettino AC, Gronthos S.

Bone. 2016 Dec;93:12-21. doi: 10.1016/j.bone.2016.09.009. Epub 2016 Sep 10.

PMID:
27622886
28.

A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.

Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, Koblar S, Harvey NL, Lopez AF, Shackleton M, Bonder CS.

Angiogenesis. 2016 Oct;19(4):463-86. doi: 10.1007/s10456-016-9520-y. Epub 2016 Jun 23.

29.

Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells.

Hemming S, Cakouros D, Vandyke K, Davis MJ, Zannettino AC, Gronthos S.

Stem Cells Dev. 2016 Jun 15;25(12):909-21. doi: 10.1089/scd.2015.0384. Epub 2016 Jun 7.

30.

Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.

Walia MK, Ho PM, Taylor S, Ng AJ, Gupte A, Chalk AM, Zannettino AC, Martin TJ, Walkley CR.

Elife. 2016 Apr 12;5. pii: e13446. doi: 10.7554/eLife.13446.

31.

Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death.

Bhattacharya S, Chalk AM, Ng AJ, Martin TJ, Zannettino AC, Purton LE, Lu J, Baker EK, Walkley CR.

Oncogene. 2016 Oct 6;35(40):5282-5294. doi: 10.1038/onc.2016.68. Epub 2016 Apr 4.

PMID:
27041566
32.

Allogeneic Mesenchymal Precursor Cells Promote Healing in Postero-lateral Annular Lesions and Improve Indices of Lumbar Intervertebral Disc Degeneration in an Ovine Model.

Freeman BJ, Kuliwaba JS, Jones CF, Shu CC, Colloca CJ, Zarrinkalam MR, Mulaibrahimovic A, Gronthos S, Zannettino AC, Howell S.

Spine (Phila Pa 1976). 2016 Sep;41(17):1331-9. doi: 10.1097/BRS.0000000000001528.

PMID:
26913464
33.

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.

Liapis V, Zinonos I, Labrinidis A, Hay S, Ponomarev V, Panagopoulos V, Zysk A, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A.

Cancer Med. 2016 Mar;5(3):534-45. doi: 10.1002/cam4.599. Epub 2016 Jan 9.

34.

Twist-1 Enhances Bone Marrow Mesenchymal Stromal Cell Support of Hematopoiesis by Modulating CXCL12 Expression.

Arthur A, Cakouros D, Cooper L, Nguyen T, Isenmann S, Zannettino AC, Glackin CA, Gronthos S.

Stem Cells. 2016 Feb;34(2):504-9. doi: 10.1002/stem.2265. Epub 2015 Dec 31.

35.

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI.

Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983.

36.

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.

Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC.

J Hematol Oncol. 2015 Oct 6;8:106. doi: 10.1186/s13045-015-0209-2.

37.

Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.

Mrozik KM, Cheong CM, Hewett D, Chow AW, Blaschuk OW, Zannettino AC, Vandyke K.

Br J Haematol. 2015 Nov;171(3):387-99. doi: 10.1111/bjh.13596. Epub 2015 Jul 20.

PMID:
26194766
38.

EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance.

Nguyen TM, Arthur A, Panagopoulos R, Paton S, Hayball JD, Zannettino AC, Purton LE, Matsuo K, Gronthos S.

Stem Cells. 2015 Sep;33(9):2838-49. doi: 10.1002/stem.2069. Epub 2015 Jun 23.

39.

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.

Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ, Walkley CR.

Sci Rep. 2015 May 6;5:10120. doi: 10.1038/srep10120.

40.

Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.

Forristal CE, Brown AL, Helwani FM, Winkler IG, Nowlan B, Barbier V, Powell RJ, Engler GA, Diakiw SM, Zannettino AC, Martin S, Pattabiraman D, D'Andrea RJ, Lewis ID, Levesque JP.

Leukemia. 2015 Oct;29(10):2075-85. doi: 10.1038/leu.2015.102. Epub 2015 Apr 29.

PMID:
25921247
41.

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.

Gupte A, Baker EK, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, Karlström Å, Mutsaers AJ, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer MA, Simpson KJ, Walkley CR.

Clin Cancer Res. 2015 Jul 15;21(14):3216-29. doi: 10.1158/1078-0432.CCR-14-3026. Epub 2015 Apr 10.

42.

Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.

Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, Zannettino AC, Vandyke K.

Exp Cell Res. 2015 Mar 1;332(1):24-38. doi: 10.1016/j.yexcr.2015.01.006. Epub 2015 Jan 28.

PMID:
25637218
43.

The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.

Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC.

Leuk Res. 2015 Mar;39(3):380-7. doi: 10.1016/j.leukres.2014.12.015. Epub 2015 Jan 7.

PMID:
25624048
44.

Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.

Martin SK, Fitter S, Dutta AK, Matthews MP, Walkley CR, Hall MN, Ruegg MA, Gronthos S, Zannettino AC.

Stem Cells. 2015 Apr;33(4):1359-65. doi: 10.1002/stem.1931.

45.

Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).

Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A.

Anticancer Res. 2014 Dec;34(12):7007-20.

PMID:
25503127
46.

Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.

Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A.

Cancer Lett. 2015 Feb 1;357(1):160-169. doi: 10.1016/j.canlet.2014.11.020. Epub 2014 Nov 15.

47.

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.

Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK.

Eur J Haematol. 2015 Apr;94(4):343-54. doi: 10.1111/ejh.12436. Epub 2014 Sep 17.

PMID:
25179233
48.

SAMSN1 is a tumor suppressor gene in multiple myeloma.

Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC.

Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002.

49.

Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.

Zinonos I, Luo KW, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ko CH, Yue GG, Lau CB, Ingman W, Ponomarev V, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A.

Int J Oncol. 2014 Aug;45(2):532-40. doi: 10.3892/ijo.2014.2468. Epub 2014 May 27.

50.

Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration.

Frith JE, Menzies DJ, Cameron AR, Ghosh P, Whitehead DL, Gronthos S, Zannettino AC, Cooper-White JJ.

Biomaterials. 2014 Jan;35(4):1150-62. doi: 10.1016/j.biomaterials.2013.10.056. Epub 2013 Nov 8.

PMID:
24215733

Supplemental Content

Loading ...
Support Center